FIRST EXPERIENCE IN SCREENING OF PROSTATE CANCER IN THE REPUBLIC OF BELARUS
Abstract
Results of prostate cancer screening in 3 regions of the Republic of Belarus for 2011 were presented. A total of 13023 men were examined. Of them, 835 (6,4 %) patients had a PSA level above 4 ng/mL. Transrectal ultrasound-guided prostate biopsy was done in 490 patients. Prostate cancer was revealed in 114 (23,3 %) patients. The percentage of patients with stage IV prostate cancer was decreased from 19 % to 7 % and the frequency of radical treatments was increased from 30 % to 70,3 % in the regions of screening
About the Authors
S. A. Krasny
N.N. Alexandrov Republic Research Center for Oncology and Medical Radiology, Minsk
Belarus
Belarus
D. T. Tarend
Belarusian Medical Academy of Postgraduate Education, Minsk
Belarus
Belarus
O. G. Sukonko
N.N. Alexandrov Republic Research Center for Oncology and Medical Radiology, Minsk
Belarus
Belarus
P. I. Moiseev
N.N. Alexandrov Republic Research Center for Oncology and Medical Radiology, Minsk
Russian Federation
Russian Federation
References
1. Егорова И.В., Максимов С.А., Дыхно Ю.А., Зуков Р.А. Диагностическое значение и оценка эффективности лечения рака предстательной железы по уровню концентрации простат- специфического антигена (ПСА) // Сибирский онкологический журнал. 2010. № 4 (40). С. 39–42.
2. Смайлит Г., Аверкин Ю., Веялки И., Красный С., Улинскас К. Сравнение выживаемости пациентов с раком простаты в Беларуси и Литве // Центрально-Европейский медицинский журнал. 2012. № 6. P. 545–549.
3. Суконко О.Г. Состояние и перспективы развития онкологии в Республике Беларусь // Онкологический журнал. 2011. Т. 5, № 4 (20). С. 5–18.
4. Aus G., Abbou C.C., Bolla M. et al. EAU guidelines on prostate cancer // Eur. Urol. 2005. Vol. 48. Р. 546–551.
5. De Koning H.J., Liem M.K., Baan C.A. et al. ERSPC. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial // Int. J. Cancer. 2002. Vol. 98. P. 268–273.
6. GLOBOCAN 2008 (МАИР), раздел информации Рака.
7. Hugosson J., Carlsson S., Aus G. et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial // Lancet Oncol. 2010. Vol. 11 (8). Р. 725–732.
8. Schroder F.H. Biomarkers and screening for prostate cancer // Ann. Oncol. 2006. Vol. 17. Suppl. 10. Р. 201–206.
9. Schroder F.H., Roobol M.J. editors. European Randomized Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results 1994–2003 // BJU Int. 2003. Vol. 92. Suppl. 2.
10. Spapen S.J., Damhuis R.A., Kirkels W.J. Trends in the curative treatment of localized prostate cancer after the introduction of prostatespecific antigen: data from the Rotterdam Cancer Registry // BJU Int. 2000. Vol. 85. Р. 474–480.
11. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement // Ann. Intern. Med. 2008. Vol. 149. Р. 185–191.
12. Wilt T.J., MacDonald R., Rutks I. et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer // Ann. Intern. Med. 2008. Vol. 148. P. 435–448.
Review
For citations:
Krasny S.A., Tarend D.T., Sukonko O.G., Moiseev P.I. FIRST EXPERIENCE IN SCREENING OF PROSTATE CANCER IN THE REPUBLIC OF BELARUS. Siberian journal of oncology. 2013;(3):66-69. (In Russ.)
Views:
606
Email this article 
